Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science (R21)

Post Date

December 21st 2011

Application Due Date

September 18th 2012

Funding Opportunity Number

RFA-CA-12-004

CFDA Number(s)

93.393
93.394
93.395

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Estimated Total Funding:

  $800000

• Award Range:

  $None - $200000

Grant Description

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), solicits grant applications proposing technically innovative feasibility studies focused on early stage development of technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of cancer-relevant biospecimens or their derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or samples derived from those biospecimens for downstream molecular analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to potentially accelerate and/or enhance research in cancer biology, prevention, diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen and/or sample quality. All projects must include quantitative milestones (i.e. technical metrics that determine whether the specific aims have been accomplished).

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-12-004.html